5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine.

Aim: This study compared the 5‐year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model. Research Design and Methods: This study was a 5‐year SURPASS‐2 trial extrapolation, with an insulin glargine arm added as an additional comparator. The 1‐year treatment effects of tirzepatide (5, 10 or 15 mg), semaglutide (1 mg) and insulin glargine on glycated haemoglobin, systolic blood pressure, low‐density lipoprotein and body weights were obtained from the SUSTAIN‐4 and SURPASS‐2 trials. We used the BRAVO model to predict 5‐year complications for each study arm under two scenarios: the 1‐year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative). Results: When compared with insulin glargine, we projected a 5‐year risk reduction in cardiovascular adverse events [rate ratio (RR) 0.64, 95% confidence interval (CI) 0.61‐0.67] and microvascular composite (RR 0.67, 95% CI 0.64‐0.70) with 15 mg tirzepatide, and 5‐year risk reduction in cardiovascular adverse events (RR 0.75, 95% CI 0.72‐0.79) and microvascular composite (RR 0.79, 95% CI 0.76‐0.82) with semaglutide (1 mg) under an optimistic scenario. Lower doses of tirzepatide also had similar, albeit smaller benefits. Treatment effects for tirzepatide and semaglutide were smaller but still significantly higher than insulin glargine under a conservative scenario. The 5‐year risk reduction in diabetes‐related complication events and mortality for the 15 mg tirzepatide compared with insulin glargine ranged from 49% to 10% under an optimistic scenario, which was reduced by 17%‐33% when a conservative scenario was assumed. Conclusion: With the use of the BRAVO diabetes model, tirzepatide and semaglutide exhibited potential to reduce the risk of macrovascular and microvascular complications among individuals with type 2 diabetes, compared with insulin glargine in a 5‐year window. Based on the current modelling assumptions, tirzepatide (15 mg) may potentially outperform semaglutide (1 mg). While the BRAVO model offered insights, the long‐term cardiovascular benefit of tirzepatide should be further validated in a prospective clinical trial. [ABSTRACT FROM AUTHOR]